An Open-label Clinical Trial to Compare the Safety and Effectiveness of Adaptive Versus Conventional Deep Brain Stimulation (ADVENT)
Primary Purpose
Parkinson Disease
Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
adaptive DBS delivered through AlphaDBS IPG System
conventional DBS delivered through AlphaDBS IPG System
Sponsored by
About this trial
This is an interventional treatment trial for Parkinson Disease focused on measuring Deep Brain Stimulation
Eligibility Criteria
Inclusion Criteria:
- Patient is ≥55 years old
- Patient has been diagnosed with levodopa-responsive idiopathic Parkinson's disease for ≥5 years
- The disease stage is II, III or IV according to the Hoehn and Yahr scale
- Patient has history of improvement of Parkinson's symptoms as a direct result of administering levodopa
- PD-related symptoms are not adequately controlled with medication, including motor complications of recent onset (>4 months duration)
- Patient experiences persistent disabling PD-related symptoms or drug side effects (e.g., dyskinesia, motor fluctuations, or disabling "off periods") despite optimal medical therapy
- Patient has been selected for bilateral STN or Gpi DBS, independently from this study, in accordance with local standard of care DBS screening
- Patient has been selected to receive Medtronic leads model 3389 or 37086, independently from this study, in accordance with local standard of care DBS screening
- Patient has DBS circuit integrity assessed and confirmed by impedance testing, before IPG implantation
- ≥6 hours per day (waking hours) with poor motor symptoms control (time "OFF" plus time "ON" with dyskinesia) despite optimal medical therapy, as assessed by the 3-day diary
- Montreal Cognitive Assessment (MoCA) >26 in MedON condition
- Beck Depression Inventory II (BDI-II) score <17 in MedON condition
- UPDRS-III improvement by ≥33% following intake of anti-parkinsonian medications
- Patient is able to understand the study requirements and the treatment procedures and has provided written informed consent to participate
- Patient is willing and capable of completing a 3-day diary and reaches a sufficient level of agreement (> 75%) with study personnel responses
- Patient has a responsible caregiver who will help completing the 3-day diary, provide feedback on activities of daily living (ADL), and ensure the patient complies with visit schedule
- Patient is willing to maintain a constant anti-PD medication treatment (best medical management) for at least one month prior to study enrollment
- Patient is willing and able to attend all study-required visits, complete the study procedures and attend appropriate follow up visits
Exclusion Criteria:
- Patient has contraindications for DBS surgery, including any intracranial abnormality (e.g., generalized atrophy, vascular malformation, hydrocephalus, hematoma, cavernous or venous angioma, tumor or metastases, midline shift, etc.) or metallic implant (e.g., aneurysm clip, cochlear implant, etc.)
- Patient has a history of suicide attempt or current active suicidal ideation as determined by a positive response to Item 2-5 of suicide ideation sub-scale of the Columbia Suicide Severity Rating Scale (CSSR-S)
- Patient has dementia, major depression, seizures, congestive heart failure, uncontrolled diabetes, dialysis, substance use disorders as described in DSM-V, or any other severe medical condition
- Patient has any medical condition that could interfere with study procedures, confound the assessment of study endpoints, or prevent a proper data collection
- Patient had confirmation of diagnosis of a terminal illness associated with survival <12 months
- Patient needs repeated MRI scans
- Patient requires diathermy, transcranial magnetic stimulation (TMS), or electroconvulsive therapy (ECT)
- Patient carries an electrical or electromagnetic implant (e.g., cochlear prosthesis, pacemaker, neurostimulator, etc.)
- Patient has, or plans to obtain, an implanted electrical stimulation medical device and/or an implanted medication pump (e.g., DUOPATM infusion pump) and/or is treated with a portable infusion pump
- Patient is on anticoagulant therapy which cannot be paused for >5 days before IPG implant surgery
- Patient with a history of cranial surgery including ablation procedure or any other previous neurosurgical procedure for the treatment of PD symptoms on either side of the brain
- Patient is currently participating in another clinical study (excluding any sub-study of the present study)
- Patient is a female who is breastfeeding or of child-bearing potential with a positive urine pregnancy test or not using adequate contraception.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Phase 1a - conventional stimulation
Phase 1b - adaptive stimulation
Arm Description
Stimulation will be delivered bilaterally to the STN or the GPi. The stimulation parameters will be based upon standard practice by the neurologist.
Stimulation will be delivered bilaterally to the STN or the GPi, with the neurologist-set therapeutic window (which corresponds to the upper and lower limits for aDBS amplitude). The stimulation will be automatically adapted according to the personalized algorithm based on real time LFP analysis.
Outcomes
Primary Outcome Measures
To assess Treatment-Emergent Adverse Events
To identify Treatment-Emergent Adverse Events (TEAEs) (including serious, device-related, stimulation-related, and/or procedure related TEAEs), discontinuations of aDBS and study discontinuation and physical or neurological findings as categorized by the Data and Safety Monitoring Board.
To compare change in Good on time (GOT) when the patient receives aDBS versus change in GOT when the patient receives cDBS.
The expected treatment effectiveness of AlphaDBS IPG System with aDBS mode (∆GOTaDBS = GOTaDBS@3-Months - GOT@Baseline) and with cDBS mode (∆GOTcDBS = GOTcDBS@3-Months - GOT@Baseline) will not differ more than two hours.
Secondary Outcome Measures
Success rate, number of patients with at least 2 hours improvement in each treatment mode
Treatement success is defined as number of patients with >2 hours ∆GOTaDBS and ∆GOTcDBS
Patient fluctuations
Number of ON/OFF transitions based on the 3-day diary
UPDRS III
UPDRS III score, in MedOFF-StimON and MedON-StimON conditions
UdysRS
Score of the Unified Dyskinesia Rating Scale (UdysRS) in MedOFF-StimON and MedON-StimON condition.
Percentage of time in which the system is used in aDBS mode
During the long term follow up, when the patient will be able to switch between programming modes, the patient preference will be assessed considering the percentage of time in which the system is used in aDBS.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05262348
Brief Title
An Open-label Clinical Trial to Compare the Safety and Effectiveness of Adaptive Versus Conventional Deep Brain Stimulation
Acronym
ADVENT
Official Title
A Prospective, Multi-center, Open-label, Pivotal Clinical Trial to Compare the Safety and Effectiveness of Adaptive Versus Conventional Stimulation in Advanced Levodopa-Responsive Parkinson's Disease Treated With Bilateral Deep Brain Stimulation
Study Type
Interventional
2. Study Status
Record Verification Date
February 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
August 2022 (Anticipated)
Primary Completion Date
August 30, 2024 (Anticipated)
Study Completion Date
December 31, 2026 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Newronika
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
5. Study Description
Brief Summary
The clinical trial aims to evaluate the safety and effectiveness of bilateral subthalamic nucleus (STN) and Globus Pallidus internus (GPi) deep brain stimulation (DBS) with the AlphaDBS IPG System when programmed in adaptive versus conventional stimulating modes. It includes an initial open-label, crossover phase and a long term follow-up phase, during which the patient is free to switch between stimulating modes.
Detailed Description
This is an international multi-center (North America and Europe) clinical trial to evaluate the safety and effectiveness of bilateral STN and GPi DBS with the AlphaDBS IPG System when programmed in adaptive (aDBS) versus conventional (cDBS) stimulating modes, in patients with advanced levodopa-responsive Parkinson's disease (PD).
The protocol is comprised of:
Phase 1: Initial Treatment Period: Cross-Over Design
Phase 1a: All patients will start the study in cDBS mode. After a 1-month post-surgical stabilization, the AlphaDBS IPG System will be turned ON in cDBS mode. Participants will complete a 1-month period of programming optimization (to fine tune medical therapies and stimulation parameters) followed by a 3-month period of cDBS.
Phase 1b: At the end of the 3-month follow up in cDBS, participants will be switched to the aDBS mode. Participants will then complete a 1-month period of optimization (to fine tune medical therapies and stimulation parameters) followed by a 3-month period of aDBS.
Phase 2: Long-term follow-up: Naturalistic Follow-up Design Patients completing Phase 1 are eligible to enter long-term follow-up for up to an additional 28 months. During this time, patients are free to change the DBS mode as preferred (with a maximum switches set by the physician). Visits at 6-month follow-ups will collect safety and efficacy data.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Parkinson Disease
Keywords
Deep Brain Stimulation
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
51 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Phase 1a - conventional stimulation
Arm Type
Active Comparator
Arm Description
Stimulation will be delivered bilaterally to the STN or the GPi. The stimulation parameters will be based upon standard practice by the neurologist.
Arm Title
Phase 1b - adaptive stimulation
Arm Type
Experimental
Arm Description
Stimulation will be delivered bilaterally to the STN or the GPi, with the neurologist-set therapeutic window (which corresponds to the upper and lower limits for aDBS amplitude). The stimulation will be automatically adapted according to the personalized algorithm based on real time LFP analysis.
Intervention Type
Device
Intervention Name(s)
adaptive DBS delivered through AlphaDBS IPG System
Other Intervention Name(s)
aDBS
Intervention Description
The AlphaDBS IPG System delivers both conventional DBS and adaptive DBS. Adaptive DBS is a programming mode that provides stimulation in a closed-loop adaptive "real-time" fashion, using a biosignal recorded from the same macro-electrodes routinely implanted for DBS as an input variable.
Intervention Type
Device
Intervention Name(s)
conventional DBS delivered through AlphaDBS IPG System
Other Intervention Name(s)
cDBS
Intervention Description
The AlphaDBS IPG System delivers both conventional DBS and adaptive DBS. Conventional DBS is programmed by DBS specialists.
Primary Outcome Measure Information:
Title
To assess Treatment-Emergent Adverse Events
Description
To identify Treatment-Emergent Adverse Events (TEAEs) (including serious, device-related, stimulation-related, and/or procedure related TEAEs), discontinuations of aDBS and study discontinuation and physical or neurological findings as categorized by the Data and Safety Monitoring Board.
Time Frame
9 months
Title
To compare change in Good on time (GOT) when the patient receives aDBS versus change in GOT when the patient receives cDBS.
Description
The expected treatment effectiveness of AlphaDBS IPG System with aDBS mode (∆GOTaDBS = GOTaDBS@3-Months - GOT@Baseline) and with cDBS mode (∆GOTcDBS = GOTcDBS@3-Months - GOT@Baseline) will not differ more than two hours.
Time Frame
9 months
Secondary Outcome Measure Information:
Title
Success rate, number of patients with at least 2 hours improvement in each treatment mode
Description
Treatement success is defined as number of patients with >2 hours ∆GOTaDBS and ∆GOTcDBS
Time Frame
9 months
Title
Patient fluctuations
Description
Number of ON/OFF transitions based on the 3-day diary
Time Frame
9 months and 36 months
Title
UPDRS III
Description
UPDRS III score, in MedOFF-StimON and MedON-StimON conditions
Time Frame
9 months and 36 months
Title
UdysRS
Description
Score of the Unified Dyskinesia Rating Scale (UdysRS) in MedOFF-StimON and MedON-StimON condition.
Time Frame
9 months and 36 months
Title
Percentage of time in which the system is used in aDBS mode
Description
During the long term follow up, when the patient will be able to switch between programming modes, the patient preference will be assessed considering the percentage of time in which the system is used in aDBS.
Time Frame
28 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
55 Years
Maximum Age & Unit of Time
95 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient is ≥55 years old
Patient has been diagnosed with levodopa-responsive idiopathic Parkinson's disease for ≥5 years
The disease stage is II, III or IV according to the Hoehn and Yahr scale
Patient has history of improvement of Parkinson's symptoms as a direct result of administering levodopa
PD-related symptoms are not adequately controlled with medication, including motor complications of recent onset (>4 months duration)
Patient experiences persistent disabling PD-related symptoms or drug side effects (e.g., dyskinesia, motor fluctuations, or disabling "off periods") despite optimal medical therapy
Patient has been selected for bilateral STN or Gpi DBS, independently from this study, in accordance with local standard of care DBS screening
Patient has been selected to receive Medtronic leads model 3389 or 37086, independently from this study, in accordance with local standard of care DBS screening
Patient has DBS circuit integrity assessed and confirmed by impedance testing, before IPG implantation
≥6 hours per day (waking hours) with poor motor symptoms control (time "OFF" plus time "ON" with dyskinesia) despite optimal medical therapy, as assessed by the 3-day diary
Montreal Cognitive Assessment (MoCA) >26 in MedON condition
Beck Depression Inventory II (BDI-II) score <17 in MedON condition
UPDRS-III improvement by ≥33% following intake of anti-parkinsonian medications
Patient is able to understand the study requirements and the treatment procedures and has provided written informed consent to participate
Patient is willing and capable of completing a 3-day diary and reaches a sufficient level of agreement (> 75%) with study personnel responses
Patient has a responsible caregiver who will help completing the 3-day diary, provide feedback on activities of daily living (ADL), and ensure the patient complies with visit schedule
Patient is willing to maintain a constant anti-PD medication treatment (best medical management) for at least one month prior to study enrollment
Patient is willing and able to attend all study-required visits, complete the study procedures and attend appropriate follow up visits
Exclusion Criteria:
Patient has contraindications for DBS surgery, including any intracranial abnormality (e.g., generalized atrophy, vascular malformation, hydrocephalus, hematoma, cavernous or venous angioma, tumor or metastases, midline shift, etc.) or metallic implant (e.g., aneurysm clip, cochlear implant, etc.)
Patient has a history of suicide attempt or current active suicidal ideation as determined by a positive response to Item 2-5 of suicide ideation sub-scale of the Columbia Suicide Severity Rating Scale (CSSR-S)
Patient has dementia, major depression, seizures, congestive heart failure, uncontrolled diabetes, dialysis, substance use disorders as described in DSM-V, or any other severe medical condition
Patient has any medical condition that could interfere with study procedures, confound the assessment of study endpoints, or prevent a proper data collection
Patient had confirmation of diagnosis of a terminal illness associated with survival <12 months
Patient needs repeated MRI scans
Patient requires diathermy, transcranial magnetic stimulation (TMS), or electroconvulsive therapy (ECT)
Patient carries an electrical or electromagnetic implant (e.g., cochlear prosthesis, pacemaker, neurostimulator, etc.)
Patient has, or plans to obtain, an implanted electrical stimulation medical device and/or an implanted medication pump (e.g., DUOPATM infusion pump) and/or is treated with a portable infusion pump
Patient is on anticoagulant therapy which cannot be paused for >5 days before IPG implant surgery
Patient with a history of cranial surgery including ablation procedure or any other previous neurosurgical procedure for the treatment of PD symptoms on either side of the brain
Patient is currently participating in another clinical study (excluding any sub-study of the present study)
Patient is a female who is breastfeeding or of child-bearing potential with a positive urine pregnancy test or not using adequate contraception.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jason Jones
Phone
901-451-4792
Email
jason.jones@newronika.com
First Name & Middle Initial & Last Name or Official Title & Degree
Costanza Conti, PhD
Phone
+393405314424
Email
costanza.conti@newronika.com
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
An Open-label Clinical Trial to Compare the Safety and Effectiveness of Adaptive Versus Conventional Deep Brain Stimulation
We'll reach out to this number within 24 hrs